Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-474-4 | CAS number: 2778-42-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Sensitisation data (human)
Administrative data
- Endpoint:
- sensitisation data (humans)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not applicable
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 993
Materials and methods
- Type of sensitisation studied:
- respiratory
- Study type:
- study with volunteers
- Principles of method if other than guideline:
- A human sensitisation study was conducted in 96 workers (employed at 3 facilities that manufacture or use TMXDI), to evaluate the clinical (questionnaire) and immunological effects (serum antibody) of TMXDI.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 1,3-bis(1-isocyanato-1-methylethyl)benzene
- EC Number:
- 220-474-4
- EC Name:
- 1,3-bis(1-isocyanato-1-methylethyl)benzene
- Cas Number:
- 2778-42-9
- Molecular formula:
- C14H16N2O2
- IUPAC Name:
- 1,3-bis(1-isocyanato-1-methylethyl)benzene
- Details on test material:
- None
Constituent 1
Method
- Type of population:
- occupational
- Ethical approval:
- not specified
- Subjects:
- - Number of subjects exposed: 96 workers at 3 facilities (two are laboratories and one is start-up plant) which produce TMXDI
- Sex: Male - Clinical history:
- Not reported
- Controls:
- Controls for ELISA:
Negative control: Serum obtained from non-exposed asymptomatic individuals
Positive control: Serum from an individual with positive antibody titers to Hexamethylene diisocyanate (HDI)-HSA - Route of administration:
- inhalation
- Details on study design:
- EXPOSURE TO TMXDI (personal monitoring):
- 31 workers were exposed to < 0.0004 ppm
- 65 workers were exposed to <0.0004 to 0.0102 ppm
- Peak exposure concentrations, due to spills, mechanical failures etc during start-up phase (1987 and 1988) of commercial production ranged from 0.3-0.5 ppm
TYPE AND DETAILS OF TEST USED
- Immunologic assays: ELISA
- Exposure period: Personal sampling (240 L) for test material was performed during routine operations, several times in 1984, 1985, and 1988; analysed by HPLC (concentrations ranged from <0.0004 to 0.0102 ppm).
- Sampling: Serum samples were collected from each of 96 workers from three facilities in 1988 or early 1989 and frozen at -20°C, until analysis.
- Method: An ELISA was conducted by blinded technicians, to estimate IgG and IgE against TMXDI-HSA (human serum albumin) in the serum of exposed workers, according to previously described protocol of Voller et al., 1976; Sepulveda et al., 1979). The endpoint was defined as the last worker serum dilution having an optical density greater than twice the mean of the negative control sera.
- Questionnaire assessment: American Thoracic Society questionnaire modified to assess relationship between symptoms and workplace exposures was used.
- Final evaluation/overall assessment: Questionnaires and serologic results (based on respiratory and ocular symptomatology were assessed individually by 2 blinded physicians from Northwestern University.
Results and discussion
- Results of examinations:
- Questionnaire Assessment: 39 workers had symptoms consistent with an irritant syndrome; 11 workers had only irritant eye symptoms while 3 had only irritant throat symptoms. For details refer to Table 1 under 'Any other information on results incl. tables'.
ELISA: No worker had symptoms suggestive of new onset asthma. One worker had low level IgE (1:10) against TMXDI-HSA; that worker reported no work related respiratory symptoms. Seven workers had very low level IgG (1:10) against TMXDI-HSA; All 8 of the workers with antibody worked in jobs with the higher exposure range (<0.0004 to 0.0102 ppm). For details refer to Table 1 under 'Any other information on results incl. tables'.
In cases of peak exposure (start up phase), none developed evidence of immunologically mediated respiratory disease due to TMXDI isocyanate and a small proportion developed low level antibody against TMXDI-HSA.
Final Evaluation/overall assessment: None of the 96 workers had an immunologically mediated respiratory or ocular disease from exposure to m-TMXDI , nor did non-immunologic sensitization appear to occur as none of the workers had histories compatible with new onset symptoms. For details refer to Table 1 under 'Any other information on results incl. tables'.
Any other information on results incl. tables
Table 1: Workers questionnaire, serologic result and final evaluation
Total | irritant symptoms | Percentage (%) | Positive antibody | Percentage (%) | No immunologic respiratory disease related to m-TMXDI | Percentage (%) | |
Group 1 (< 0.0004 ppm) | 31 | 14 | 48 | 0 | 0 | 31 | 100 |
Group 2 (0.0004 to 0.0102 ppm) | 65 | 25 | 39 | 8 | 12 | 65 | 100 |
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of the study, apart from upper respiratory or occular irritant symptoms, there was low incidence of positive serology and no clinical hypersensitivity in worker population on exposure to m-TMXDI.
- Executive summary:
A human sensitisation study was conducted using 96 workers employed at three facilities that manufacture or use TMXDI to evaluate the clinical (questionnaire) and immunological effects (serum antibody).
The study population was divided into three groups based upon relative exposure (31 workers at <0.0004 ppm and 65 workers at < 0.0004 to 0.0102 ppm) and duration of exposure was up to 3 years. IgE and IgG against TMXDI conjugated to HSA (TMXDI-HSA) were determined by ELISA.
There were no workers with immunologically induced disease due to TMXDI nor were there any workers whose questionnaires suggested new onset of asthma. Approximately 48% of workers experienced some irritant symptoms, mostly upper respiratory or ocular. Very low level IgG against TMXDI-HSA was present in 8% of workers, all of whom were in the highest exposure category. No immunologic respiratory disease has been identified in this worker population. Further, in cases of peak exposure (start up phase), none developed evidence of immunologically mediated respiratory disease due to TMXDI isocyanate and a small proportion developed low level antibody against TMXDI-HSA. Hence, under the conditions of the study, apart from upper respiratory or ocular irritant symptoms, there was low incidence of positive serology and no clinical hypersensitivity in worker population on exposure to m-TMXDI.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)